Search Results for: Gallium 68
Gallium 68 PET/CT Scanning for Neuroendocrine Tumors — Information and Locations (updated January 26, 2019)
The US Food and Drug Administration’s (FDA) June 1, 2016 approval of the Gallium-68 PET/CT DOTATATE scan using NETSPOT® heralded a new age of nuclear imaging for neuroendocrine tumors in the United States.
PLEASE SCROLL DOWN FOR A STATE-BY STATE LIST … READ MORENext Generation Germanium-68/Gallium-68 Generator
ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies in Germany, and RadioMedix Inc., a clinical stage biotechnology company in Houston, Texas, announced on December 8, 2020, that the U.S. Food …
READ MORENETSPOT Gallium-68 Code for Medicare/Medicaid and Private Payors
Another exciting step forward for the NET community! Advanced Accelerator Applications announced that the Centers for Medicare & Medicaid Services (CMS) has granted NETSPOT® Transitional Pass-Through Status under an “A-code” (A9587) for …
READ MOREFirst Northeastern Facility Offers Gallium-68 DOTATOC PET/CT Imaging for Carcinoid and Neuroendocrine Cancer Patients
When Brian Hakimian had the 68Gallium DOTATOC PET/CT scan at the Icahn School of Medicine, Mount Sinai in New York City on January 14, 2015, he became the first carcinoid patient to undergo this novel imaging test at a northeastern facility. Now in clinical…
READ MORE
First Northeastern Facility Offers Gallium-68 DOTATOC PET/CT Imaging for Carcinoid and Neuroendocrine Cancer Patients
When Brian Hakimian had the 68Gallium DOTATOC PET/CT scan at the Icahn School of Medicine, Mount Sinai in New York City on January 14, 2015, he became the first carcinoid patient to undergo this novel imaging test at a northeastern facility. Now in clinical…
READ MORE
Gallium-68 Scan Coming to NOLANETS for Carcinoid and Neuroendocrine Tumor Patients
Dr. Eugene A. Woltering has announced that the Gallium-68 DOTATATE PET/CT scan is going to be available beginning in the summer of 2014 through The New Orleans Louisiana Neuroendocrine Tumor Specialists (NOLANETS) Neuroendocrine Tumor Program at …
READ MOREFDA Grants Orphan Drug Designation to Gallium-68 DOTATOC for Neuroendocrine Tumor Management
BREAKING NEWS – The radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine tumors. This designation is significant…
READ MORE
1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT)
Since 1997, when he first used the radiolabeled peptide Y-90 DOTATOC (a somatostatin analogue) to treat a 15-year-old boy with a rare neuroendocrine tumor, called paraganglioma, and saw the boy go from being wheelchair-bound and in terrible pain to …
READ MORE
Excel Diagnostics and Nuclear Oncology Center Selected For New Investigational PRRT Treatment and Gallium Scan for Carcinoid and Neuroendocrine Tumor Patients
For carcinoid, pancreatic neuroendocrine tumor, and other NET cancer patients seeking the most advanced nuclear medicine opportunities in the United States, Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, in collaboration with…
READ MORE
2nd World Congress on Ga-68, Molecular Imaging & Targeted Radionuclide Therapy
Chandigarh, India will be the site of the 2nd World Congress on Ga-68 (Generators and Novel Radiopharmaceuticals), Molecular Imaging (PET/CT), Targeted Radionuclide Therapy and Dosimetry: On the Way to Personalized Medicine from February 28 through…
READ MORE
